GALNT4 in Patients With Acute Coronary Syndrome

Changes of GALNT4 and the Relationship With PSGL-1on Monocytes and Hs-CRP in Blood of Patients With Coronary Heart Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03335514

Enrollment

100

Registered

2017-11-07

Start date

2017-09-01

Completion date

2018-12-31

Last updated

2019-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

GALNT4

Brief summary

The expression of GALNT4 in blood with acute coronary syndrome

Detailed description

Emerging evidences have linked GALNTs to cardiovascular disease or susceptibility to CAD.GALNT4, a member of the GalNAc-Ts family,contributes to the initiation of O-linked. Polymorphisms in GALNT4 have been linked with incidence of MI in an Irish population, probably that O-glycosylation of PSGL-1 by GalNAc-T4 may be important for many P-selectin mediated inflammation.However, there is few relevant studies about the expression of GALNT4 in patients with acute coronary syndrome.This study valuates the expression of GALNT4 in patients with acute coronary syndrome.

Interventions

DIAGNOSTIC_TESTexpression of GALNT4

Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* diagnosed as acute coronary syndrome,including STEMI,NSTE-ACS,or diagnosed as SAP by CAG. * with left ventricular ejection fraction（LVEF）\>=45% * written informed consents are obtained * admitted within 24 hours after chest pain attacked(except SAP)

Exclusion criteria

* • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy * complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction * with acute or chronic infection, surgery or trauma in the last month * secondary hypertension, severe liver dysfunction,severe renal insufficiency * with abnormal thyroid function or allergy to iodine agent * refusal to sign the informed consent

Design outcomes

Primary

Measure	Time frame	Description
the expression of GALNT4	12 months	Realtime RCR measure the expression of galnt4 in peripheral blood

Secondary

Measure	Time frame	Description
MACEs during 12-month follow-up	12 months	All major adverse cardiac events( MACEs) including death, myocardial infarction, heart failure are recorded

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026